Back to Careers

Juvena gets FDA Orphan Drug nod for muscle regeneration therapy

Back to Careers

Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1

Back to Careers

Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”

Back to Careers

Dr. Hanadie Yousef attends the Global Healthspan Summit in Riyadh, Saudi Arabia, organized by the Hevolution Summit as an invited speaker showcased on their Entrepreneurship Spotlight panel

Back to Careers

Congratulations to our outstanding DL Engineer, Tejaswini Ganapathi for presenting a poster based on her AI research at Juvena entitled “Prediction of transcriptomic response to perturbagens in unobserved cell lines and cell states” at the ML Drug Discovery Symposium at Broad Institute of MIT and Harvard on October 27, 2023. We presented our exciting development of a generalized machine learning system that predicts biological effects such as gene expression changes on cells.

Back to Careers

Congratulations to our outstanding DL Engineer, Tejaswini Ganapathi for presenting a poster based on her AI research at Juvena entitled “Prediction of transcriptomic response to perturbagens in unobserved cell lines and cell states” at the ML Drug Discovery Symposium at Broad Institute of MIT and Harvard on October 27, 2023. We presented our exciting development of a generalized machine learning system that predicts biological effects such as gene expression changes on cells.

Back to Careers

Juvena’s CSO, Dr. Jeremy O’Connell, and VP Dr. Mo Tabrizi attend and present, both through oral presentation and poster, our DM1 lead program at the annual Myotonic Dystrophy Foundation Conference which we are proud to sponsor

Back to Careers

Our Director of Discovery and Platform, Dr. Thach Mai and CSO Dr. Jeremy O’Connell share more about Juvena’s discovery platform and approach to identifying and developing a regenerative biologics for promoting lung epithelium re-growth for the treatment of idiopathic pulmonary fibrosis at the IPF 2023 Annual summit.

Back to Careers

CEO Dr. Hanadie Yousef is recognized by Business Insider on their shortlist of 30 under 40 Transforming Healthcare